Company intelligence / Profile preview

Novotel

Beijing, China

Ownership: Private
Development stage: Commercial

Overview

The company has multiple programs at various stages, including Phase I clinical trials for recombinant human hyaluronidase injection and several biosimilars in late-stage development or market application submission. Multiple products in clinical and preclinical stages including biosimilars and novel biologics

Therapeutic areas: OtherEndocrinology
Modalities: Recombinant proteinSmall moleculePeptidesBiosimilar
Industry: Biotech

Partnerships

Zencore Biologics

Beyond the preview

Go deeper on Novotel.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novotel.

Explore the full profile